BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.

Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...

Valencia have issued a medical update on centre-back César Tárrega after Sunday’s match at Getafe. The club said in a ...

Sixth overall for Lantern’s A.I.-driven precision oncology pipelineOrphan designation expands LP-284's potential for an ...

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.

In this episode of Talking Under Water, Mandy Crispin and Bob Crossen discuss the EPA’s proposal to establish a national primary drinking water regulation for perchlorate under the Safe Drinking Water ...

Acalabrutinib was associated with increased PFS and a 24% reduction in time to next treatment or death in long-term results. Concurrent acalabrutinib, bendamustine, and rituximab (ABR) in the ...

Emerging therapies such as bezuclastinib and elenestinib show promise in improving disease control with potentially fewer toxicities. Other novel strategies, such as immune-based therapies, are under ...

Bone marrow aspirate concentrate (BMAC) is a common treatment for joint injuries. The invasive therapy involves extracting bone marrow-often from the hip-and concentrating it to preserve stem cells ...